Comparative pharmacokinetics of levofoxacin in healthy volunteers and in patients suffering from typhoid fever

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 1, 2013, Pages 147-154

  Usman, Muhammad ^a   Ashraf, Muhammad ^a   Khokhar, Muhammad Imran ^b   Ashiq, Bilal ^a   Masood, Muhammad Irfan ^a   Afzal, Shehryar ^a   Omer, Ovais ^a   Ali, Mohsin ^c   Imran Qadir, M ^c  

^a UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (Pakistan)

^b SERVICES HOSPITAL   (Pakistan)

^c GC UNIVERSITY   (Pakistan)

Author keywords

HPLC; Levofoxacin; Pharmacokinetics; Typhoid fever; Volunteers

Indexed keywords

LEVOFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TYPHOID FEVER;

EID: 84874685924     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Wynckel A, Toupance O, Melin JP, David C, Lavaud S, Wong T, Lamiable D and Chanard J. Treatment of legionellosis with ofoxacin in kidney transplanted patients. Lack of interaction with cyclosporin A. Presse Med. (1991) 20: 291-293.
2. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA and Corrado M. Levofoxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. (1998) 42: 1098-1104.
3. McGregor JC, Allen GP and Bearden DT. Levofoxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther. Clin. Risk Manag. (2008) 4: 843-853.
4. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R and Del FA. Levofoxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med. (2005) 353: 977-987.
5. Klesel N, Geweniger KH, Koletzki P, Isert D, Limbert M, Markus A, Riess G, Schramm H, Seibert G and Iyer P. Activity of levofoxacin, ofoxacin, D-ofoxacin and ciprofoxacin against systemic and respiratory tract infections in laboratory animals. Drugs (1995) 49: 211-214.
6. Crump JA, Barrett TJ, Nelson JT and Angulo FJ. Reevaluating fuoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi salmonellae. Clin. Infect. Dis. (2003) 37: 75-81.
7. Lyon DJ, Cheung SW, Chan CY and Cheng AF. Rapid HPLC assay of clinafoxacin, feroxacin, levofoxacin, sparfoxacin and tosufoxacin. J. Antimicrob. Chemother. (1994) 34: 446-448.
8. Bergeron MG and Bergeron Y. Infuence of endotoxin on the intrarenal distribution of gentamicin, netilmicin, tobramycin, amikacin, and cephalothin. Antimicrob. Agents Chemother. (1986) 29: 7-12.
9. Mojtahedzadeh M and Mahmoudi L. Aminoglycoside resistance in ICUs: are we running out of drugs, for bad bugs. Iranian J. Pharm. Res. (2011)10: 391-392.
10. Easmon CS, Crane JP and Blowers A. Effect of ciprofoxacin on intracellular organisms: in-vitro and in-vivo studies. J. Antimicrob. Chemother. (1986) 18: 43-48.
11. th ed., John Wiley and Sons, New York (1999).
12. Benko R, Matuz M, Doro P, Peto Z, Molnar A, Hajdu E, Nagy E, Gardi J and Soos G. Pharmacokinetics and pharmacodynamics of levofoxacin in critically ill patients with ventilator-associated pneumonia. Int. J. Antimicrob. Agents (2007) 30: 162-168.
13. Lee CK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M and Zeitlin PL. Levofoxacin pharmacokinetics in adult cystic fbrosis. Chest (2007) 131: 796-802.
14. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA and Corrado M. Levofoxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. (1998) 42: 1098-1104.
15. Fish DN and Chow AT. The clinical pharmacokinetics of levofoxacin. Clin. Pharmacokinet. (1997) 32: 101-119.
16. Wong FA, Juzwin SJ and Flor SC. Rapid stereospecifc high-performanceliquidchromatographic determination of levofoxacin in human plasma and urine. J. Pharm. Biomed. Anal. (1997) 15: 765-771.
17. Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC and Fish DN. Levofoxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob. Agents Chemother. (2006) 50: 1937-1945.
18. Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC and Bartlett JA. Pharmacokinetics and safety of levofoxacin in patients with human immunodefciency virus infection. Antimicrob. Agents Chemother. (1994) 38: 799-804.
19. Albarellos GA, Ambros LA and Landoni MF. Pharmacokinetics of levofoxacin after single intravenous and repeat oral administration to cats. J. Vet. Pharmacol. Ther. (2005) 28: 363-369.